<unk>  is indicated for the treatment of adults with relapsed or refractory large B-cell lymphoma.
Loncastuximab tesirine
Polatuzumab vedotin
Margetuximab
Isatuximab
Moxetumomab pasudotox
Dinutuximab
Neratinib
Imatinib